Pharmacotherapy of insomnia

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1243-1260

  Ioachimescu, Octavian C ^a   El Solh, Ali A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Benzodiazepine; Benzodiazepine receptor agonist; Insomnia; Melatonin; Melatonin receptor agonist; Total sleep time

Indexed keywords

AGO 178; AGOMELATINE; AMAVIL; AMITRIPTYLINE; AMITRIPTYLINE PLUS PERPHENAZINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BROTIZOLAM; DIAZEPAM; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLUNITRAZEPAM; FLUOXETINE PLUS OLANZAPINE; FLURAZEPAM; GABAZOLPIDEM; HYPNOTIC AGENT; INTERMEZZO; LIMBITROL; LOPRAZOLAM; LORMATAZEPAM; MELATONIN; MELATONIN RECEPTOR AGONIST; MIRTAZAPINE; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; QUAZEPAM; QUETIAPINE; RAMELTEON; SENTRAZOLPIDEM; TASIMELTEON; TEMAZEPAM; TRAZODONE; TREZAMINE TRAZODONE; TRIAZOLAM; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ATAXIA; BEDTIME DOSAGE; CIRCADIAN RHYTHM; COGNITION; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; HALLUCINATION; HANGOVER; HEADACHE; HUMAN; HYPNOSIS; INSOMNIA; MAINTENANCE THERAPY; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PARESTHESIA; POLYSOMNOGRAPHY; PRIAPISM; PSYCHOPHARMACOTHERAPY; RECOMMENDED DRUG DOSE; REM SLEEP; REVIEW; SINGLE DRUG DOSE; SLEEP WALKING; SOMNOLENCE; TABLET; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; HYPNOTICS AND SEDATIVES; NONPRESCRIPTION DRUGS; RISK FACTORS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84861362284     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.683860     Document Type: Review

References (183)

1. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/ International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry 2011;69:592-600
2. Sarsour K, Kalsekar A, Swindle R, et al. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep 2011;34:443-50
3. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews 2002;6:97-111
4. Hohagen F, Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-4
5. Roth T, Drake C. Defining insomnia: the role of quantitative criteria. Sleep 2006;29:424-5
6. Roth T, Jaeger S, Jin R, et al. Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biological Psychiatry 2006;60:1364-71
7. Jansson-Frojmark M, Lindblom K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. Journal of Psychosomatic Research 2008;64:443-9
8. Morin CM, Belanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009;169:447-53
9. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3:S7-10
10. Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997;20:715-23
11. Ohayon MM, Caulet M, Priest RG, Guilleminault C. DSM-IV and ICSD-9 - insomnia symptoms and sleep dissatisfaction. Br J Psychiatry 1997;171:382-8
12. Li RH, Wing YK, Ho SC, Fong SY. Gender differences in insomnia-a study in the Hong Kong Chinese population. J Psychosom Res 2002;53:601-9
13. Stone KC, Taylor DJ, McCrae CS, et al. Nonrestorative sleep. Sleep Med Rev 2008;12:275-88
14. Taylor DJ. Insomnia and depression. Sleep 2008;31:447-8
15. Buysse DJ, Angst J, Gamma A, et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008;31:473-80
16. Pigeon WR, Hegel M, Unutzer J, et al. Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep 2008;31:481-8
17. Liu X. Sleep and adolescent suicidal behavior. Sleep 2004;27:1351-8
18. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders 2011;135:10-19
19. Available from: http://www. sleepfoundation.org/sites/default/files/ sleepinamericapoll/ SIAP-2011-Summary-of-Findings.pdf [Accessed January 2012] 2011
20. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(Suppl):16-23
21. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999;22(Suppl 2):S354-8
22. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population. J Gen Intern Med 1995;10:25-32
23. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-73
24. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl 2):S386-93
25. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002;51:229-35
26. American Psychiatry Association. DSM-5 development Sleep-wake disorders. Available from: http://www. dsm5.org/proposedrevision/pages/ sleep-wakedisorders.aspx [Last accessed January 2012] 2010
27. Bonnet MH. Hyperarousal and insomnia. Sleep Med Rev 2010;14:33
28. Bhat A, Shafi F, El Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother 2008;9:351-62
29. Montgomery P, Dennis J. A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Med Rev 2004;8:47-62
30. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159:5-11
31. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-9
32. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998 - 2004). Sleep 2006;29:1398-414
33. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7:215-25
34. Health NIo. National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep 2005;28:59
35. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504
36. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2-8
37. Zhang D, Pan ZH, Awobuluyi M, Lipton SA. Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends Pharmacol Sci 2001;22:121-32
38. Olsen RW, Sieghart W. International union of pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008;60:243-60
39. Burt DR. Reducing GABA receptors. Life Sci 2003;73:1741-58
40. Smith AJ, Alder L, Silk J, et al. Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol 2001;59:1108-18
41. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796-800
42. Rudolph U, Mohler H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 2004;44:475-98
43. Bowery NG. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 1993;33:109-47
44. Couve A, Moss SJ, Pangalos MN. GABAB receptors: a new paradigm in G protein signaling. Mol Cell Neurosci 2000;16:296-312
45. Ng GY, Clark J, Coulombe N, et al. Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem 1999;274:7607-10
46. Shimada S, Cutting G, Uhl GR. gamma-Aminobutyric acid A or C receptor? gamma-Aminobutyric acid rho 1 receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive gammaaminobutyric acid responses in Xenopus oocytes. Mol Pharmacol 1992;41:683-7
47. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7
48. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33
49. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991;52(Suppl):38-41
50. Mendelson W. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992;53(Suppl):2
51. Roehrs T, Merlotti L, Zorick F, Roth T. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology 1992;108:67-71
52. Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 1987;317:722-8
53. Roehrs T, Pedrosi B, Rosenthal L, Roth T. Hypnotic self administration and dose escalation. Psychopharmacology 1996;127:150-4
54. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002;22:285-93
55. Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in michigan nursing homes. J Am Geriatr Soc 2005;53:955-62
56. Kelly KD, Pickett W, Yiannakoulias N, et al. Medication use and falls in community-dwelling older persons. Age Ageing 2003;32:503-9
57. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303-7
58. Ambien [package insert]. Sanofi- Synthelabo, Inc.; New York, NY: 2004
59. Pressman MR, Mahowald MW, Schenck CH. Sleep terrors/ sleepwalking-not REM behavior disorder. Sleep 2005;28:278-9
60. Micromedex 2.0. Available from: http://www.thomsonhc.com/micromedex2/ librarian [Last accessed January 2012] 2012
61. Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469-80
62. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-36
63. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9
64. Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep 2011;34:207-12
65. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31:79-90
66. Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008;31:1371-8
67. Zolpimist [package insert]. ECR Pharmaceuticals; Richmond, VA: 2010
68. Intermezzo [package insert]. Transcept Pharmaceuticals, Inc.; Pt. Richmond, CA: 2011
69. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-89
70. Elie R, Ruther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999;60:536-44
71. Mendelson WB. Sleepwalking associated with zolpidem. J Clin Psychopharmacol 1994;14:150
72. Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy 1996;16:687-9
73. Sattar SP, Ramaswamy S, Bhatia SC, Petty F. Somnambulism due to probable interaction of valproic acid and zolpidem. Ann Pharmacother 2003;37:1429-33
74. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-7
75. Lange CL. Medication-associated somnambulism. J Am Acad Child Adolesc Psychiatry 2005;44:211-12
76. Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem-sleepwalking: a case report. Arch Phys Med Rehabil 2005;86:1265-6
77. Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 2009;10:616-20
78. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin 2010;26:1423-31
79. Roth T, Hull SG, Lankford DA, et al. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008;31:1277-84
80. Sonata [package insert]. Wyeth; Philadelphia, PA: 2004
81. Damgen K, Luddens H. Zaleplon displays selectivity to recombinant GABA-A receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25:10
82. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002;451:103-10
83. Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21
84. Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-ofthe- night awakening. J Clin Sleep Med 2006;2:417-23
85. Huang YS, Hsu SC, Liu SI, Chen CK. A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia. Chang Gung Med J 2011;34:50-6
86. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20
87. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116-25
88. Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2011. [Epub ahead of print]
89. Lunesta [package insert]. Sepracor; Marlborough, MA: 2005
90. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9
91. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91
92. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-68
93. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720-7
94. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients withinsomnia. Curr Med Res Opin 2006;22:1633-42
95. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006;108:1402-10
96. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60
97. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65:551-62
98. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010;202:171; e171-171 e111
99. Fava M, Asnis GM, Shrivastava RK, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry 2011;72:914-28
100. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:892-7
101. Fava M, Schaefer K, Huang H, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011;72:473-9
102. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6:487-95
103. Wikner BN, Kallen B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol 2011;31:356-9
104. Krystal AD. A compendium of placebo-controlled trials of the risks/ benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265-74
105. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005;20:27-37
106. Miyamoto M, Nishikawa H, Doken Y, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004;27:1319-25
107. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998;21:52-68
108. Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603
109. MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991;30:371-6
110. Montes LGA, Ontiveros Uribe MP, Cortes Sotres J. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, cross-over study. J Psychiatry Neurosci 2003;28:6
111. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50
112. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004;116:91-5
113. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167
114. Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000;343:1070-7
115. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54
116. Rondanelli M, Opizzi A, Monteferrario F, et al. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc 2011;59:82-90
117. Rozerem [package insert]. Takeda Laboratories; Lincolnshire, Ill: 2005
118. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006;60:97-108
119. Stevenson S, Cornelissen K, Clarke E. Study of the absorbtion, metabolism and excretion of ramelteon (TAK-375) [abstract]. Clin Pharmacol Ther 2004;75:1
120. Tolbert DK, Karim A, Zhao Z. Evaluation of the single and multiple doses pharmacokinetics of ramelteon (TAK-375) in subjects with and without renal impairment [abstract]. J Clin Pharmacol 2004;44:1
121. Sainati SMK, A, Tolbert D. Effects of multiple doses of fluoxetine on the systemic exposure of a single dose of ramelteon (TAK-375) in healthy adults [abstract]. Sleep 2004;27
122. Karim AT, Tolbert D, Cao C. Effects of fluconazole and ketoconazole on the pharmacokinetics of ramelteon (TAK-376) in normal healthy male and female subjects [abstract]. Sleep 2004;27:2
123. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2- receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303-7
124. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
125. Zammit GR, Roth T, Erman M. Double-blind placebo-controlled polysomnography and outpatient trial to evaluate the efficacy of ramelteon in adult patients with chronic insomnia [abstract]. Sleep 2006;28:1
126. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-18
127. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007;47:485-96
128. Stubbs C, Karim A. A safety, tolerance and pharmacokinetic study of five single doses of TAK-375 in healthy adults. Sleep 2003;26:1
129. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149-57
130. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19:1057-65; discussion 1066-1057
131. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/ MT2 receptor agonist. Neuropharmacology 2005;48:301-10
132. Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10:305-18
133. Arendt J, Rajaratnam SM. Melatonin and its agonists: an update. Br J Psychiatry 2008;193:267-9
134. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482-91
135. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009;10:691-701
136. Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011;21(Suppl 4):S703-9
137. Descamps A, Rousset C, Millan MJ, et al. Influence of the novel antidepressant and melatonin agonist/ serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology 2009;205:93-106
138. Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005;63:298-304
139. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004;27:1441-2
140. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66:469-76
141. Walsh JKE, Erman M, Erwin CW. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998;13:8
142. Yamadera H, Nakamura S, Suzuki H, Endo S. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 1998;52:439-43
143. Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983;16:139-44
144. Carson CC III, Mino RD. Priapism associated with trazodone therapy. The Journal of Urology 1988;139:369-70
145. Compton-Mcbride SS, Schweitzer PK, Walsh JK. Most commonly used drugs to treat insomnia in 2002. Sleep 2004;27(Suppl):1
146. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002;35:165-74
147. Hohagen F, Montero RF, Weiss E, et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 1994;244:65-72
148. Winokur A, DeMartinis NA III, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64:1224-9
149. Schittecatte M, Dumont F, Machowski R, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46:197-201
150. Winokur A, Sateia MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000;48:75-8
151. Sorensen M, Jorgensen J, Viby-Mogensen J, et al. A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985;71:339-46
152. Rodenbeck A, Cohrs S, Jordan W, et al. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) 2003;170:423-8
153. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996;29:187-92
154. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453-63
155. Hsu TR, Rogowski R, Roth T. Low-dose doxepin in the treatment of primary insomnia [abstract 0150]. Program and abstracts of the Asociated Professional Sleep Societies, 19th annual meeting; 18 - 23 June 2005; Denver, Colorado
156. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61
157. Salin-Pascual RJ, Herrera-Estrella M, Galicia Polo L. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999;46:3
158. Walsh JK, Perlis M, Rosenthal M, et al. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006;2:35-41
159. Roth T, Wright KP Jr, Walsh J. Effect of tiagabine on sleep in elderly subjectswith primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006;29:335-41
160. Deacon S, Staner L, Staner C, et al. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 2007;30:281-7
161. Lundahl J, Staner L, Staner C, et al. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology (Berl) 2007;195:139-46
162. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000;295:226-32
163. Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 2011;339:99-105
164. Ancoli-Israel S, Vanover KE, Weiner DM, et al. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 2011;12:134-41
165. Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther 2010;332:281-90
166. Abrams JK, Johnson PL, Hay-Schmidt A, et al. Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 2005;133:983-97
167. Da Settimo F, Taliani S, Trincavelli ML, et al. GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 2007;14:2680-701
168. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66
169. Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opinion Ther Patents 2010;20:307-24
170. Cai JQ, Cooke FE, Sherborne BS. Antagonists of the orexin receptors. Expert Opinion Ther Patents 2006;16:631-46
171. Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8:977-87
172. Boss C, Brisbare-Roch C, Jenck F. Biomedical application of Orexin/ Hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903
173. Herring W.J.B.Budd K.S.Hutzelmann J.et al. Efficacy and tolerability of the dual orexin receptor antagonist MK-4305 in patients with primary insomnia: Randomized, controlled, adaptive crossover polysomnography study Presented at SLEEP 2010, 24th Assoc. Prof. Sleep Soc.; 5 - 9 June; San Antonio, Texas; 2010
174. Dingemanse JD, Dorffner G, Hajak G, et al. Proof-of-concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist. Presented at WorldSleep 07, 5th International Congress of the World Federation of Sleep Research and Sleep Medicine Societies; 2 - 6 September; Cairns, Austria; 2007
175. Di Fabio RG, Gerrard P, Porter R, et al. Bis-amido piperidine derivatives as in vitro and in vivo potent dual orexin receptor antagonists. Presented at 238th ACS Natl. Meeting; 16 - 20 August; Washington, D.C; 2009
176. Bettica P, Nucci G, Pyke C, et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol 2011. [Epub ahead of print]
177. Ratti E. Psychiatry: an innovative drug discovery pipeline. Available from: http:// www.gsk.com/investors/presentations/ 2007/neurosciences-seminar- dec07/ emiliangelo-ratti.pdf 2007
178. Di Fabio RG, Gerrard P, Porter R, et al. Bis-amido piperidine derivatives as in vitro and in vivo potent dual orexin receptor antagonists. Presented at 238th ACS Natl. Meeting; 16 - 20 August; Washington, D.C; 2009
179. Various studies on GW679769 (NCT00650871, NCT00280423, NCT00280436, NCT00354809). Available from: www.clinicaltrials.gov [Last accessed January 2012] 2012
180. A study with GW597599 and GR205171: potential new drugs for the treatment of insomnia (NCT00606697). Available from: www.clinicaltrials.gov [Last accessed January 2012] 2012
181. Richardson GS, Roehrs TA, Rosenthal L. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:5
182. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(Suppl):34-39; discussion 40-32
183. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998;60:610-15